Pricing Log in Create free account

Opus Genetics, Inc. (IRD) vs Relmada Therapeutics, Inc. (RLMD)

Opus Genetics, Inc. and Relmada Therapeutics, Inc. are both Biotechnology companies. Opus Genetics, Inc. and Relmada Therapeutics, Inc. are of similar size ($341.3M and $336.9M). Relmada Therapeutics, Inc. has the higher net margin (0.00% vs −1,091.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Relmada Therapeutics, Inc. leads on 7 and Opus Genetics, Inc. on 5.

Valuation

Metric IRD RLMD Biotechnology median
P/E n/m n/m 8.50
P/S 36.91 n/m 9.71
P/B n/m 1.69 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 31.47 n/m 9.21
Earnings yield (33.86%) (29.03%) (33.15%)
Free cash flow yield (11.61%) (36.56%) (25.50%)

Profitability

Metric IRD RLMD Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (513.47%) 0.00% 0.00%
Net margin (1,091.82%) 0.00% 0.00%
Free cash flow margin (412.61%) 0.00% 0.00%
Return on equity (4,796.52%) (55.66%) (56.36%)
Return on assets (163.50%) (51.57%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IRD RLMD Biotechnology median
Revenue growth (TTM) (36.09%) — 6.02%
EPS growth (last fiscal year) 62.79% 45.28% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IRD RLMD Biotechnology median
Debt to equity (2.69) 0.00 0.00
Current ratio 12.19 29.52 4.72
Net debt to EBITDA 1.17 1.57 0.96

Dividend

Metric IRD RLMD Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric IRD RLMD Biotechnology median
Market cap 336.94m 341.34m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack